News & Media
Press Center & More

Up-to-date press releases and statements in all categories, as well as materials for journalists.

May 20, 2022
Statement
COVID-19
Global health

Novavax Files in the European Union for Expanded Conditional Marketing Authorization of COVID-19 Vaccine as a Booster in Individuals Aged 18 and Over

May 13, 2022
Statement
COVID-19

Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan

May 9, 2022
Press release
Corporate and finance

Novavax Reports First Quarter 2022 Financial Results and Operational Highlights

Media contact

Email: [email protected]
Phone: (240) 720-7804

Images, videos, and files for media use

Extensive materials for members of the press, including broadcast, online, film, radio and print journalists.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.